

Pseudothrombocytopenia by ethylenediaminetetraacetic acid can jeopardize patient safety – a case report

Cristina Collazo Abal, Leticia Rodríguez Calviño, Laura Rollán Manso,
M.C. Ferreirós Domínguez, M.J. Lorenzo Lorenzo, Cristina Regojo Balboa,
Arturo Fernández Nogueira

Servicio de Análisis Clínicos, Hospital Álvaro Cunqueiro, Vigo, Spain

ARTICLE INFO

Corresponding author:

Cristina Collazo Abal
Servicio de Análisis Clínicos
Hospital Álvaro Cunqueiro
Vigo
Spain
E-mail: cristinacollazo@gmail.com

Key words:

platelet count, thrombocytopenia,
phlebotomy, patient safety,
complete blood cell count

ABSTRACT

Pseudothrombocytopenia by ethylenediaminetetraacetic acid (EDTA) is an infrequent phenomenon of *in vitro* platelet agglutination due to the presence of antiplatelet autoantibodies. It has no clinical significance, but misdiagnosis may lead to clinical or therapeutic decision-making. In this study, we report a case of an 8-year-old boy with no history of platelet disorder presenting a low platelet count and a peripheral blood smear showing clumping of platelets by EDTA. The initial diagnosis hypothesis was of an idiopathic thrombocytopenic purpura, and an unnecessary bone marrow aspirate was made even though he did not have personal or family history of bleeding. A second sample collected in sodium citrate confirmed the pseudothrombocytopenia by EDTA. In conclusion, the laboratory should enhance a strong relationship with clinicians trying to avoid misunderstandings as that reflected in this case report. It should be reminded that, in those cases where a pseudothrombocytopenia by EDTA is suspected, a blood smear is mandatory

to confirm platelet clumps and blood must be tested anticoagulated with another anticoagulant (i.e., sodium citrate or heparin).



INTRODUCTION

Several preanalytical factors could impact platelets evaluation and jeopardize patient safety (1). Therefore, laboratory professional should guarantee preanalytical procedures to avoid the following source of platelets variability:

- improperly fasting time (2,3)
- improperly tourniquet application time (4,5)
- unstandardized patient posture (6)
- improper order of evacuated tubes (7,8)
- improper blood venous sampling (9)

According to the World Health Organization (WHO), patient safety is the absence of preventable harm to a patient during the process of health care and reduction of risk of unnecessary harm associated with health care to an acceptable minimum (7). The work in healthcare services should focus in the culture of patient safety, understanding that the problem is often a succession of several oversights or errors, from which we can learn and implement solutions to prevent them in the future.

Ethylenediaminetetraacetic acid (EDTA) is a calcium chelator (10), widely used as an anticoagulant for a complete blood count test because it generally does not distort blood cells. The term pseudothrombocytopenia by EDTA define a low platelet count in patients without any bleeding tendency, and platelet distribution curve that indicates platelet aggregation (11). Moreover, the patient should present a normal platelet count if a different anticoagulant is used (12). The aim of this report is to show that a pseudothrombocytopenia by EDTA can jeopardize the patient safety.

CLINICAL-DIAGNOSTIC CASE

An 8-year-old boy was referred to paediatric onco-haematology for presenting a two-year evolution thrombocytopenia with a platelet count below $20 \times 10^3/\mu\text{L}$ (Reference Interval: $130-400 \times 10^3/\mu\text{L}$) with normal values of white blood cells (WBC) and haemoglobin (Hb) (Table 1). He did not have a significant past medical history, besides his familial hypercholesterolemia, and his clinical examination was unremarkable.

The initial diagnosis hypothesis was of an idiopathic thrombocytopenic purpura even though he did not have personal or family history of bleeding. A bone marrow aspirate was made, with no significant anomalies in the sample obtained. It was described as a normocellular marrow, showing trilinear haematopoiesis, with a preserved myeloid/erythroid ratio and a megakaryocytic series without significative dysmorphias. At that moment the clinician realized that there was a commentary on the platelet count remarking the presence of plentiful platelet clumps in all the previous laboratory reports. The complete blood count was repeated in the emergency laboratory. The platelet count was of $16 \times 10^3/\mu\text{L}$ together with a platelet clumps alarm in the automated cell counter (Advia 2120, Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA), without alterations in the other two haematological series (Table 1). Given this result, a peripheral blood smear was made, and multiple platelet clumps were observed (Figure 1). This was remarked in the laboratory report and a new sample was collected using an evacuated tube with 3.2% sodium citrate, as anticoagulant additive (BD Vacutainer). The platelet count in this sample was normal (Table 1) and this result was discussed with the clinician. Physicians decide to perform a new blood collection with both anticoagulants 14 days after these results to confirm the pseudothrombocytopenia by EDTA (Table 1).

Table 1 Laboratory results

Laboratory test (unit)	Anticoagulant	Platelet (x10 ³ /μL)	WBC (x10 ³ /μL)	Neutrophil (x10 ³ /μL)	Lymphocyte (x10 ³ /μL)	Mono-cyte (x10 ³ /μL)	Eosinophil (x10 ³ /μL)	Basophil (x10 ³ /μL)	Hb (g/dL)	RBC (x10 ⁶ /μL)	Hct (%)	MCV (fL)
1 st October 4 th	EDTA	20	8.70	4.69	3.00	0.62	0.34	0.05	13.9	4.61	38.1	82.6
2 nd November 6 th	EDTA	16	6.15	2.25	2.00	1.49	0.20	0.04	13.5	4.54	38.3	84.4
2 nd November 6 th	Na citrate	160	NA									
3 rd November 20 th	EDTA	5	7.94	3.69	3.14	0.56	0.23	0.02	13.1	4.58	38.3	83.6
3 rd November 20 th	Na citrate	198	NA									


DISCUSSION

EDTA-dependent pseudothrombocytopenia is an infrequent phenomenon of *in vitro* platelet agglutination due to the presence of antiplatelet autoantibodies (13,14); its incidence has been reported to be between 0.10 and 0.29% (15). As described in our case the agglutination *in vitro* results in a decrease in platelet count, typically below 100x10³/μL with the presence of a “platelet aggregation” alert flag from the analyser (16), the peripheral blood smear must be observed in order to confirm the presence of platelet clumps (17). In addition, a new blood sample from the same patient using sodium citrate as anticoagulant is the most suitable sample for the platelet count (18). The laboratory professional has the responsibility of detecting these false thrombocytopenias and notifying this information in the laboratory report (19). Likewise, the clinician should consider this condition in order to avoid unnecessary diagnostic tests and therapeutic interventions with the aim of preserving patient safety. Therefore, we would like to highlight the following learning points from this case report:

- The spurious low platelet count must be reported together with a commentary on the presence of platelet clumps that underestimate the real count.
- The clinical laboratory has an essential role over patient safety, but more efforts are required to prevent inappropriate clinical or therapeutic decision-making.

In conclusion, the laboratory should enhance a strong relationship with clinicians trying to avoid misunderstandings as that reflected in this case report. It should be reminded that, in those cases where a pseudothrombocytopenia by EDTA is suspected, a blood smear is mandatory to confirm platelet clumps and blood must be tested anticoagulated with other anticoagulant (i.e., sodium citrate or heparin).

Figure 1 Peripheral blood smear from blood sample collected with EDTA (May-Grünwald-Giemsa stained) observed in optical microscopy



Note: Arrows indicate platelet clumps at 400X (A) and at 1000X magnification (B).

Disclosures and contributions

Cristina Collazo Abal is the main responsible for the study conception design, intellectual content and drafting of this paper. All other authors confirmed they have contributed significantly to the analysis and interpretation of data, revising, and approving the article. All authors declare no conflicts of interest.



REFERENCES

1. Lima-Oliveira G, Volanski W, Lippi G, Picheth G and Guidi GC. Pre-analytical phase management: a review of the procedures from patient preparation to laboratory analysis. *Scand J Clin Lab Invest* 2017;77:153–163.
2. Arredondo ME, Aranda E, Astorga R, Brennan-Bourdon LM, Campelo MD, Flores S, Medel C, Manríquez I, Ochoa P, Varela B, Salinas CV and Lima-Oliveira G. Breakfast can Affect Routine Hematology and Coagulation Laboratory Testing: An Evaluation on Behalf of COLABIOCLI WG-PRE-LATAM. *TH Open* 2019;03:e367–376.
3. Guidi GC, Simundic AM, Salvagno GL, Aquino JL and Lima-Oliveira G. To avoid fasting time, more risk than benefits. *Clin Chem Lab Med* 2015;53:e261–264.
4. Lima-Oliveira G, Lippi G, Salvagno GL, Gaino S, Poli G, Gelati M, Picheth G and Guidi GC. Venous stasis and whole blood platelet aggregometry: A question of data reliability and patient safety. *Blood Coagul Fibrinolysis* 2015;26: 665–668.
5. Lima-Oliveira G, Lippi G, Salvagno GL, Montagnana M, Scartezini M, Guidi GC and Picheth G. Transillumination: A new tool to eliminate the impact of venous stasis during the procedure for the collection of diagnostic blood specimens for routine haematological testing. *Int J Lab Hematol* 2011; 33:457–462.
6. Lima-Oliveira G, Guidi GC, Salvagno GL, Danese E, Montagnana M and Lippi G. Patient posture for blood collection by venipuncture: recall for standardization after 28 years. *Rev Bras Hematol Hemoter* 2017;39:127–132.
7. Lima-Oliveira G, Lippi G, Salvagno GL, Montagnana M, Poli G, Solero GP, Picheth G and Guidi GC. K 3 EDTA Vacuum Tubes Validation for Routine Hematological Testing. *ISRN Hematol* 2012;2012:875357.
8. Lima-Oliveira G, Lippi G, Salvagno GL, Montagnana M, Poli G, Solero GP, Picheth G and Guidi GC. Brand of dipotassium

EDTA vacuum tube as a new source of pre-analytical variability in routine haematology testing. *Br J Biomed Sci* 2013; 70:6–9.

9. Simundic AM, Bölenius K, Cadamuro J, Church S, Cornes MP, van Dongen-Lases EC, Eker P, Erdeljanovic T, Grankvist K, Guimaraes JT, Hoke R, Ibarz M, Ivanov H, Kovalevskaya S, Kristensen GBB, Lima-Oliveira G, Lippi G, von Meyer A, Nybo M, De la Salle B, Seipelt C, Sumarac Z, Vermeersch P; Working Group for Preanalytical Phase (WG-PRE), of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI). Joint EFLM-COLABIOCLI Recommendation for venous blood sampling. *Clin Chem Lab Med* 2018;56:2015-2038.

10. Lima-Oliveira G, Monneret D, Guerber F and Guidi GC. Sample management for clinical biochemistry assays: Are serum and plasma interchangeable specimens? *Crit Rev Clin Lab Sci* 2018;55:480–500.

11. Gschwandtner ME, Siostrzonek P, Bodinger C, Neunteufl T, Zauner C, Heinz G, Maurer G and Panze S. Documented sudden onset of pseudothrombocytopenia. *Ann Hematol* 1997;74:283–285.

12. Akyol L, Onem S, Ozgen M and Sayarlioglu M. Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia in a patient with systemic lupus erythematosus and lupus nephritis. *Eur J Rheumatol* 2016;3:36–37.

13. Pegels JG, Bruynes EC, Engelfriet CP and von dem Borne AE. Pseudothrombocytopenia: an immunologic study on platelet antibodies dependent on ethylene diamine tetraacetate. *Blood* 1982;59:157–161.

14. Casonato A, Bertomoro A, Pontara E, Dannhauser D, Lazzaro AR and Girolami A. EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIb-IIIa. *J Clin Pathol* 1994;47: 625–30.

15. Yoneyama A and Nakahara K. EDTA-dependent pseudothrombocytopenia--differentiation from true thrombocytopenia. *Nihon Rinsho* 2003;61:569–574.

16. Lin J, Luo Y, Yao S, Yan M, Li J, Ouyang W and Kuang M. Discovery and Correction of Spurious Low Platelet Counts due to EDTA-Dependent Pseudothrombocytopenia. *J Clin Lab Anal* 2015;29:419–426.

17. Sarasa-Bosque C, Arruga-Mombiola C and Denizon-Arranz S. Aprendiendo de los errores: fenómeno EDTA. *Semer-Med Fam.* 2009;35:106–107.

18. Lippi G and Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. *Clin Chem Lab Med* 2012;50:1281–1285.

19. Cadamuro J, Simundic AM, Ajzner E and Sandberg S. A pragmatic approach to sample acceptance and rejection. *Clin Biochem* 2017;50:579–581.